STK4

Across TCGA pan-cancer cohorts, STK4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STK4 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher STK4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STK4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where STK4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.865	0.459	.001	9	view →
HNSC	DFS	Median	All	0.909	0.994	.006	6	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.393	.047	4	view →
CCRCC	DFS	Median	All	0.665	0.812	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

STK4–LUAD (DFS)

Open the LUAD breakdown →